Table 2: Treatment-related adverse events during TVR/PegIFN/RBV triple therapy.

TVR/PegIFN/RBV triple therapy > 4 weeks ()

Overall treatment-related AEs during TVR/PegIFN/RBV10 (92%)
Discontinuation of TVR/PegIFN/RBV due to AEs1 (9%)
Anemia with hemoglobin levels below 10 g/dL5 (45%)
 EPO administration5 (45%)
 Blood transfusion4 (36%)
Leukopenia with a WBC count below 1.5/nL5 (45%)
 GCF administration5 (45%)
Renal failure2 (18%)
Infection3 (27%)
Skin changes2 (18%)
Anorectal pruritus1 (9%)
Death0

TVR/PegIFN/RBV triple therapy was discontinued in 1 patient after 4 weeks due to a nonresponse.